VIP

Vasoactive Intestinal Peptide (VIP), also known as vasoactive intestinal polypeptide or PHM-27, is a neuropeptide that has garnered significant attention in laboratory research for its diverse physiological effects. This research-grade compound is classified as a neuropeptide and operates through a well-characterised mechanism involving specific cell surface receptors. In research models, VIP functions by binding to specific receptors on cell surfaces, which leads to the activation of adenylate cyclase and subsequent increases in cyclic AMP levels. This biochemical cascade results in smooth muscle relaxation, vasodilation, and modulation of immune responses. Additionally, studies indicate that VIP influences circadian rhythms by acting on the suprachiasmatic nucleus in the brain. Laboratory investigations have demonstrated several primary research effects of VIP. Studies show improvements in circadian rhythm regulation, making it valuable for chronobiology research. Research models have also indicated that VIP reduces inflammation in chronic inflammatory response syndrome (CIRS), suggesting potential applications in inflammatory research. Furthermore, laboratory studies demonstrate that VIP enhances neuroprotection and cognitive function, promotes vasodilation and improves blood flow, and modulates immune system activity. The current evidence grade for VIP is classified as B, indicating moderate research support. There are a limited number of human trials investigating VIP, primarily focusing on its effects in CIRS and neuroprotection. These studies suggest potential benefits, but researchers note that larger, more comprehensive trials are needed to confirm efficacy and safety. Current research gaps include long-term safety data and broader population studies, highlighting the importance of continued laboratory investigation.